Z Li, S Richards, HK Surks, A Jacobs… - Clinical & …, 2018 - academic.oup.com
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of
relapsing multiple sclerosis (MS). In the Phase II/III trials, patients received 12 or 24 mg/day …